Form 4: Relay Therapeutics Director Exercises Stock Options

Director Jami Rubin exercised stock options for 42,242 shares of Relay Therapeutics common stock at a price of $5.04 per share on June 10, 2024.

Summary

• On June 10, 2024, Jami Rubin, a director of Relay Therapeutics, Inc., exercised stock options to purchase 42,242 shares of common stock at $5.04 per share.
• The exercise was a cash exercise, and the underlying shares were not subsequently sold.
• Following the transaction, Rubin directly owns 67,242 shares of Relay Therapeutics common stock.
• The stock options were granted with a vesting schedule of sixteen equal quarterly installments starting October 10, 2019, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock option exercise, with no inherent positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their confidence in the company's prospects.

Comparison to Industry Standards

• Stock option exercises are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of sixteen equal quarterly installments is a typical vesting arrangement.
• The disclosure is consistent with SEC regulations regarding insider trading and Form 4 filings.
• Comparable companies such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals also have directors and executives who regularly exercise stock options.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it is a routine exercise of existing stock options.
• The exercise increases the number of outstanding shares, potentially diluting existing shareholders' ownership slightly.

Key Dates